Directorate Change

RNS Number : 1102V

Mediclinic International plc

31 October 2017

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic" or "the Company")

APPOINTMENT OF DR MUHADDITHA YAHYA AL HASHIMI AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

31 October 2017

Mediclinic announces that Dr Muhadditha Yahya Al Hashimi will join its Board as an Independent Non-Executive Director with effect from 1 November 2017.

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

"Dr Al Hashimi has extensive experience and knowledge of the healthcare and higher education sectors in the UAE, together with strategic and tactical expertise in operations and fiscal management. The Board is delighted to welcome Dr Al Hashimi as a Non-Executive Director of the Company and we look forward to her contribution."

Dr Al Hashimi is also a member of the Board of Trustees and the Audit and Compliance Committee of the University of Sharjah, a member of the Board of Trustees of the UAE Nursing and Midwifery Council and of the UAE Genetics Diseases Association, and the Campus Director of Higher Colleges of Technology Sharjah Women's College in the UAE.

Prior to her current positions, Dr Al Hashimi was the Executive Dean of the Faculty of Health Sciences, Higher Colleges of Technology; Acting Deputy Vice Chancellor - Academic Affairs at the Higher Colleges of Technology; Chief Executive Officer of the Mohammed Bin Rashid Al Maktoum Academic Medical Center in Dubai; Deputy Chief Executive Officer of Tatweer, LLC; Chief Executive Officer of Dubai Healthcare City (both members of Dubai Holding); and Director of Education of the Harvard Medical School Dubai Centre.

Dr Al Hashimi obtained a Doctorate in Public Health (University of Texas, USA), a Master's Degree in Clinical Laboratory Sciences (University of Minnesota, USA) and a Bachelor's Degree in Medical Technology (University of Minnesota, USA).

There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment. Dr Al Hashimi's fees will amount to £60,000 per annum, in-line with current independent non-executive directors.

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact: